From Fangs to Pharmacology: The Future of Snakebite Envenoming Therapy
Open accessThe DOI matches its Crossref record.
Abstract
The snake is the symbol of medicine due to its association with Asclepius, the Greek God of medicine, and so with good reasons. More than 725 species of venomous snakes have toxins specifically evolved to exert potent bioactivity in prey or victims, and snakebites constitute a public health hazard of high impact in Asia, Africa, Latin America, and parts of Oceania. Parenteral administration of antivenoms is the mainstay in snakebite envenoming therapy. However, despite well-demonstrated efficacy and safety of many antivenoms worldwide, they are still being produced by traditional animal immunization procedures, and therefore present a number of drawbacks. Technological advances within biopharmaceutical development and medicinal chemistry could pave the way for rational drug design approaches against snake toxins. This could minimize the use of animals and bring forward more effective therapies for snakebite envenomings. In this review, current stateof- the-art in biopharmaceutical antitoxin development is presented together with an overview of available bioinformatics and structural data on snake venom toxins. This growing body of scientific and technological tools could define the basis for introducing a rational drug design approach into the field of snakebite envenoming therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Gutiérrez, J. M., Calvete, J. J., Habib, A. G., Harrison, R. A., Williams, D. J., & Warrell, D. A. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.63 · Cited by 955
Self-citationCauses and Consequences of Snake Venom Variation
Casewell, N. R., Jackson, T. N. W., Laustsen, A. H., & Sunagar, K. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.05.006 · Cited by 396
Self-citationBittenbinder, M. A., van Thiel, J., Cardoso, F. C., Casewell, N. R., Gutiérrez, J.-M., Kool, J., & Vonk, F. J. (2024) · Communications Biology · doi:10.1038/s42003-024-06019-6 · Cited by 132
Self-citationSenji Laxme, R. R., Attarde, S., Khochare, S., Suranse, V., Martin, G., Casewell, N. R., Whitaker, R., & Sunagar, K. (2021) · PLOS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0009150 · Cited by 101
“…treatment failure due to venom variation, stringent evaluation of the preclinical efficacy of antivenoms, ideally by an independent external laboratory or at the very least the publication of manufacturer-generated data for independent assessment, should be mandatory prior to marketing [14,97,98].”
Toxin synergism in snake venoms
Laustsen, A. H. (2016) · Toxin Reviews · doi:10.1080/15569543.2016.1220397 · Cited by 65
Self-citation
Metadata
- Authors
- Laustsen, A., Engmark, M., Milbo, C., Johannesen, J., Lomonte, B., Gutiérrez, J., & Lohse, B.
- Venue
- Current Pharmaceutical Design
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2016-11-10
- Volume
- 22
- Issue
- 34
- Pages
- 5270-5293
- ISSN
- 1381-6128 (ISSN-L)
- OpenAlex
- W2468932669
- Cited by
- 119
- References
- 0
- FWCI
- 13.70
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: From Fangs to Pharmacology: The Future of Snakebite Envenoming Therapy. https://app.cochat.ai/papers/10.2174/1381612822666160623073438
- The paper
- Laustsen, A., Engmark, M., Milbo, C., Johannesen, J., Lomonte, B., Gutiérrez, J., & Lohse, B. (2016). From Fangs to Pharmacology: The Future of Snakebite Envenoming Therapy. Current Pharmaceutical Design. https://doi.org/10.2174/1381612822666160623073438
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.